Oncological outcomes of surgical management for T2N0M0 glottic laryngeal squamous cell carcinoma.

Jian Zhou, Cheng-Zhi Xu, Xiao-Ke Zhu, Yue Yang, Liang Zhou, Hong-Li Gong, Lei Tao
Author Information
  1. Jian Zhou: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China. ORCID
  2. Cheng-Zhi Xu: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China.
  3. Xiao-Ke Zhu: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China.
  4. Yue Yang: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China.
  5. Liang Zhou: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China.
  6. Hong-Li Gong: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China.
  7. Lei Tao: Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital Fudan University Shanghai China. ORCID

Abstract

Objectives: The research aimed to evaluate the clinical treatment outcomes of T2N0M0 glottic laryngeal squamous cell carcinoma (LSCC) patients who underwent laryngectomy.
Methods: Retrospective review of 533 T2N0M0 glottic LSCC patients.
Results: Five-year cancer-specific survival (CSS) rate was 90.0%, and the overall survival (OS) rate was 89.1%. No statistically difference was found between the patients who have undergone total laryngectomy (5-year disease-free survival[DFS] = 80.7%, and the CSS = 86.7%) and those who have had partial laryngectomy (the 5-year DFS = 85.3%, and CSS = 91.1%). There was no difference in the CSS and DFS rates between patients with negative margins and those with positive margins following postoperative radiotherapy (PORT) ± chemotherapy (the CSS: 90.8% vs. 81.8%,  = 0.458 and 5-year DFS: 84.6% vs. 79.5%,  = 0.371). Patients who underwent vertical partial laryngectomy (VPL) had better survival (5-year OS was 91.9%, and the CSS was 92.8%) than those who underwent cricohyoidoepiglottopexy (CHEP) or cricohyoidopexy (CHP) (the 5-year OS = 83.8%,  = 0.022 and CSS = 84.9%,  = 0.038).
Conclusions: Surgery remains the gold standard for treating T2N0M0 glottic LSCC patients because it can achieve satisfactory oncological outcomes. Regarding the systemic conditions, the effect of partial laryngectomy is similar to that of total laryngectomy. Moreover, partial laryngectomy preserves the function of the larynx. VPL may be superior to CHP/CHEP, depending upon the invasiveness of the tumor.

Keywords

References

  1. Laryngoscope. 2015 Sep;125(9):2093-8 [PMID: 26109043]
  2. J Laryngol Otol. 2016 May;130(S2):S75-S82 [PMID: 27841116]
  3. Head Neck Oncol. 2010 Jul 30;2:20 [PMID: 20673360]
  4. Cancer Res Treat. 2018 Jan;50(1):156-163 [PMID: 28301924]
  5. CA Cancer J Clin. 2020 Jan;70(1):7-30 [PMID: 31912902]
  6. Head Neck. 2014 May;36(5):611-6 [PMID: 23595858]
  7. Laryngoscope. 2000 Nov;110(11):1811-4 [PMID: 11081590]
  8. Int J Cancer. 2010 Dec 15;127(12):2893-917 [PMID: 21351269]
  9. Otolaryngol Head Neck Surg. 2014 Feb;150(2):237-44 [PMID: 24255085]
  10. Eur Arch Otorhinolaryngol. 2013 Jan;270(1):287-91 [PMID: 22460527]
  11. Anticancer Res. 2016 Jun;36(6):2903-7 [PMID: 27272804]
  12. Cancer. 2004 May 1;100(9):1786-92 [PMID: 15112257]
  13. Acta Otolaryngol. 2018 Nov;138(11):1043-1050 [PMID: 30776268]
  14. J Clin Oncol. 2001 Oct 15;19(20):4029-36 [PMID: 11600604]
  15. Eur Arch Otorhinolaryngol. 2013 Jul;270(7):2079-87 [PMID: 23568036]
  16. Acta Otolaryngol. 2012 May;132(5):546-51 [PMID: 22264025]
  17. Arch Otolaryngol Head Neck Surg. 1990 Jul;116(7):830-5 [PMID: 2363922]
  18. Head Neck. 2012 Jan;34(1):23-33 [PMID: 21374753]
  19. J Clin Oncol. 2003 Feb 1;21(3):496-505 [PMID: 12560441]
  20. Head Neck. 2016 Jan;38(1):36-43 [PMID: 24996171]
  21. Head Neck. 2010 Jan;32(1):1-7 [PMID: 19953627]
  22. Head Neck. 2017 Jan;39(1):71-81 [PMID: 27453475]
  23. Pharmacoeconomics. 2014 Sep;32(9):865-82 [PMID: 24842794]
  24. Acta Otolaryngol. 2013 Jan;133(1):91-8 [PMID: 23106387]
  25. ORL J Otorhinolaryngol Relat Spec. 2011;73(6):336-42 [PMID: 22005723]
  26. Radiat Oncol. 2012 Nov 19;7:193 [PMID: 23164282]
  27. J Clin Oncol. 2018 Apr 10;36(11):1143-1169 [PMID: 29172863]
  28. J Surg Oncol. 2019 Sep;120(4):698-706 [PMID: 31273803]
  29. Acta Otorhinolaryngol Ital. 2012 Aug;32(4):256-7 [PMID: 23093816]
  30. J Natl Compr Canc Netw. 2020 Jul;18(7):873-898 [PMID: 32634781]
  31. Anticancer Res. 2009 Feb;29(2):661-6 [PMID: 19331217]
  32. Oncol Lett. 2020 Jul;20(1):921-930 [PMID: 32566021]
  33. CA Cancer J Clin. 2013 Jan;63(1):11-30 [PMID: 23335087]

Word Cloud

Created with Highcharts 10.0.0laryngectomyT2N0M0patients5-yearoutcomesglotticLSCCpartial8% = 0underwentsurvivalCSSlaryngealsquamouscellcarcinomarate90OS1%differencetotal7%marginsvsVPL9%oncologicalObjectives:researchaimedevaluateclinicaltreatmentMethods:Retrospectivereview533Results:Five-yearcancer-specific0%overall89statisticallyfoundundergonedisease-freesurvival[DFS] = 80CSS = 86DFS = 853%CSS = 91DFSratesnegativepositivefollowingpostoperativeradiotherapyPORT ± chemotherapyCSS:81458DFS:846%795%371Patientsverticalbetter9192cricohyoidoepiglottopexyCHEPcricohyoidopexyCHPOS = 83022CSS = 84038Conclusions:SurgeryremainsgoldstandardtreatingcanachievesatisfactoryRegardingsystemicconditionseffectsimilarMoreoverpreservesfunctionlarynxmaysuperiorCHP/CHEPdependinguponinvasivenesstumorOncologicalsurgicalmanagement

Similar Articles

Cited By